Deutsche Bank analyst James Shin maintains $Eli Lilly and Co (LLY.US)$ with a buy rating, and adjusts the target price from $1,025 to $1,015.
According to TipRanks data, the analyst has a success rate of 42.9% and a total average return of -6.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Eli Lilly and Co (LLY.US)$'s main analysts recently are as follows:
Post Q3 earnings, heightened scrutiny from the Street on Zepbound scripts and inventory may be anticipated, according to an analyst. Despite this, there is a belief that the demand for GLP1 remains robust. Among the large-cap biopharma companies in the U.S., Eli Lilly is still considered to have the most compelling growth narrative.
Eli Lilly's recent quarter revealed uneven results for Mounjaro and Zepbound, although it was clarified that the deviations were due to inventory dynamics rather than supply and demand factors. Despite the third-quarter irregularities, the overall stance on Eli Lilly remains positive, albeit with a slight reduction in the projections for Mounjaro and Zepbound.
The reduction in the anticipated value for Eli Lilly follows their Q3 report, with expectations that there is significant ground to cover in Q4. This comes as a result of fluctuations in channel inventories and the delay of direct-to-consumer efforts to the middle of the quarter.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
德意志銀行分析師James Shin維持$禮來 (LLY.US)$買入評級，並將目標價從1,025美元下調至1,015美元。
根據TipRanks數據顯示，該分析師近一年總勝率為42.9%，總平均回報率為-6.5%。
此外，綜合報道，$禮來 (LLY.US)$近期主要分析師觀點如下：
一位分析師表示，在第三季度業績發佈後，華爾街可能會加強對Zepbound腳本和庫存的審查。儘管如此，人們認爲對GLP1的需求仍然強勁。在美國的大盤生物製藥公司中，禮來仍被認爲是最引人注目的增長敘事。
禮來公司最近一個季度顯示，Mounjaro和Zepbound的業績參差不齊，儘管有人澄清說，偏差是由於庫存動態而不是供需因素造成的。儘管第三季度存在違規行爲，但禮來公司的總體立場仍然樂觀，儘管對Mounjaro和Zepbound的預測略有下降。
禮來公司預期價值的下降是在其第三季度報告之後出現的，預計第四季度還有大量工作要做。這是渠道庫存波動以及直接面向消費者的努力推遲到本季度中期的結果。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
